BACKGROUND: Allergy immunotherapy during early childhood may have potential benefits for the prevention of asthma and allergy morbidity. However, subcutaneous immunotherapy has not yet been prospectively researched in children younger than 4 years, primarily because of safety concerns, including the fear and psychological distress young children may experience with repeated needle injections. OBJECTIVE: To quantify fear in atopic children younger than 4 years with a history of wheezing who are receiving subcutaneous immunotherapy. METHODS:Fear of injection was graded during a total of 788 immunotherapy injection visits in 18 children (age, 37 months; SD, 9 months) receiving subcutaneous allergy immunotherapy. The parent and the injection nurse assigned fear scores on a scale of 0 to 10 after each injection visit. RESULTS: At the time of analysis, children had a median of 49 injection visits (range, 12-88) during a median study period of 81.5 weeks (range, 15-165 weeks). Fifteen children (83%) lost their fear of injections during the study. A fear score of 0 was achieved after a mean of 8.4 visits (SD, 7.4). The more injection visits were missed, the more likely children were to retain fear of injections (hazard ratio, 0.13; 95% confidence interval, 0.02-1.02; P=.05). Age, adverse events, number of injections at each visit, and change of injection personnel were not associated with increased fear. CONCLUSION: Our analysis suggests that most children receiving weekly subcutaneous immunotherapy lose their fear of injections during the treatment course. Children with increased intervals between visits may be at higher risk of experiencing fear of injections. CLINICAL TRIAL REGISTRATION: clinicaltrial.gov identifier NCT01028560.
RCT Entities:
BACKGROUND:Allergy immunotherapy during early childhood may have potential benefits for the prevention of asthma and allergy morbidity. However, subcutaneous immunotherapy has not yet been prospectively researched in children younger than 4 years, primarily because of safety concerns, including the fear and psychological distress young children may experience with repeated needle injections. OBJECTIVE: To quantify fear in atopic children younger than 4 years with a history of wheezing who are receiving subcutaneous immunotherapy. METHODS: Fear of injection was graded during a total of 788 immunotherapy injection visits in 18 children (age, 37 months; SD, 9 months) receiving subcutaneous allergy immunotherapy. The parent and the injection nurse assigned fear scores on a scale of 0 to 10 after each injection visit. RESULTS: At the time of analysis, children had a median of 49 injection visits (range, 12-88) during a median study period of 81.5 weeks (range, 15-165 weeks). Fifteen children (83%) lost their fear of injections during the study. A fear score of 0 was achieved after a mean of 8.4 visits (SD, 7.4). The more injection visits were missed, the more likely children were to retain fear of injections (hazard ratio, 0.13; 95% confidence interval, 0.02-1.02; P=.05). Age, adverse events, number of injections at each visit, and change of injection personnel were not associated with increased fear. CONCLUSION: Our analysis suggests that most children receiving weekly subcutaneous immunotherapy lose their fear of injections during the treatment course. Children with increased intervals between visits may be at higher risk of experiencing fear of injections. CLINICAL TRIAL REGISTRATION: clinicaltrial.gov identifier NCT01028560.
Authors: Linda Cox; Harold Nelson; Richard Lockey; Christopher Calabria; Thomas Chacko; Ira Finegold; Michael Nelson; Richard Weber; David I Bernstein; Joann Blessing-Moore; David A Khan; David M Lang; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher Randolph; Diane E Schuller; Sheldon L Spector; Stephen Tilles; Dana Wallace Journal: J Allergy Clin Immunol Date: 2010-12-03 Impact factor: 10.793
Authors: Wayne J Morgan; Debra A Stern; Duane L Sherrill; Stefano Guerra; Catharine J Holberg; Theresa W Guilbert; Lynn M Taussig; Anne L Wright; Fernando D Martinez Journal: Am J Respir Crit Care Med Date: 2005-08-18 Impact factor: 21.405
Authors: Peter D Sly; Attilio L Boner; Bengt Björksten; Andy Bush; Adnan Custovic; Philippe A Eigenmann; James E Gern; Jorrit Gerritsen; Eckard Hamelmann; Peter J Helms; Robert F Lemanske; Fernando Martinez; Soren Pedersen; Harald Renz; Hugh Sampson; Erika von Mutius; Ulrich Wahn; Patrick G Holt Journal: Lancet Date: 2008-09-20 Impact factor: 79.321
Authors: Theresa W Guilbert; Wayne J Morgan; Robert S Zeiger; Leonard B Bacharier; Susan J Boehmer; Marzena Krawiec; Gary Larsen; Robert F Lemanske; Andrew Liu; David T Mauger; Chris Sorkness; Stanley J Szefler; Robert C Strunk; Lynn M Taussig; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2004-12 Impact factor: 10.793
Authors: L Jacobsen; B Niggemann; S Dreborg; H A Ferdousi; S Halken; A Høst; A Koivikko; L A Norberg; E Valovirta; U Wahn; C Möller Journal: Allergy Date: 2007-08 Impact factor: 13.146